​Swissmedic, the agency for therapeutic products in Switzerland, has extended the temporary approval of the vaccine against COVID-19 Nuvaxovid, the American biotech company Novavax, the manufacturer of this vaccine, informed DPA.
This vaccine is now approved for “active immunization” to prevent SARS-CoV-2 SARS-CoV-2 disease in adolescents (12-17 years) and as a heterologous and homologous booster dose for adults aged 18 years and older, according to Agerpres, which refers to the DPA.
The company announced that it is currently testing the efficacy and safety of Nuvaxovid as a booster, and preclinical data suggest that the vaccine elicits an immune response against Omicron variants, including the BA.4/5 type.
Source: Hot News RO
Robert is an experienced journalist who has been covering the automobile industry for over a decade. He has a deep understanding of the latest technologies and trends in the industry and is known for his thorough and in-depth reporting.